The Department of Biochemistry Presents Bhussry Series featuring Blythe D. Shepard, PhD – “Elucidating the hepatoprotective effects of SGLT2 inhibition in diabetic TallyHo mice”
“Elucidating the hepatoprotective effects of SGLT2 inhibition in diabetic TallyHo mice”
Blythe D. Shepard, PhD
Department of Human Science
Georgetown University
Blythe.Shepard@georgetown.edu
Sodium-glucose co-transporters (SGLTs) serve to reabsorb glucose in the kidney. Recently these transporters, mainly SGLT2, have emerged as new therapeutic options for patients with diabetes and kidney disease; by inhibiting glucose reabsorption, they promote glycosuria, weight loss, and improve glucose tolerance. While its impacts on the kidney are well known, we and others have determined that Empagliflozin, one of the most well-characterized SGLT2 inhibitors, also leads to cardiometabolic protection. Using diabetic TallyHo mice, we have found that SGLT2 inhibition can mitigate the development of nonalcoholic fatty liver disease leading to an attenuation in hepatic steatosis, changes in insulin tolerance, and a decrease in visceral fat. Ongoing efforts are focused on identifying the mechanism(s) by which the modulation of renal glucose handling translates to improved liver function.
Join Zoom Meeting
https://georgetown.zoom.us/j/99910323814?pwd=MEVYR0U2RnZ0TVVVbit1ZHJwUzVnQT09